Background: Contemporary hypertension treatment has shifted toward intensive blood pressure targets and earlier use of fixed-dose combination therapy. The 2024 ESC guideline further emphasizes stricter systolic blood pressure (SBP) control and preferential use of single-pill fixed-dose combinations over multiple separately administered agents. Accordingly, treatment may progress from low-dose dual-combination therapy to low-dose triple-combination therapy, followed […]
